Ert Pompe denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to ERT for Pompe Disease

A quantity-limits denial for enzyme replacement therapy in Pompe disease typically occurs when the dosing submitted on the claim or prior-authorization request exceeds the quantity the plan has pre-authorized per dispensing period. Because ERT dosing is determined by the patient's actual body weight and is recalculated at each infusion, the approved quantity on a standing prior authorization can become outdated — particularly for pediatric patients who are growing, or for adults whose weight has changed.

This is most often a recalculation or documentation gap, not a clinical determination that the therapy is inappropriate.

## Why This Denial Is Appealable

The FDA-approved prescribing label specifies how ERT dosing is calculated (weight-based). When the prescribed quantity reflects the label's weight-based calculation applied to the patient's current documented weight, the quantity is medically necessary by definition — and the plan's fixed limit does not override the label. Your appeal should demonstrate that the quantity prescribed is exactly what the label formula requires for this patient's current weight, as documented in the chart.

## Federal Appeal Framework

• ERISA §503 requires a full-and-fair internal review with a written explanation of the specific quantity limit being applied.
• ACA §2719 provides access to independent external review. A quantity-limits denial that conflicts with the FDA-approved weight-based dosing regimen is strong grounds for IRO reversal.
• The external-review window is generally within approximately four months of denial; confirm the exact deadline on your Explanation of Benefits.
• Expedited review is appropriate given that missing or delaying an infusion in Pompe disease can result in measurable irreversible decline.

## Concrete Appeal Steps

1. Obtain the specific quantity limit from UHC's denial letter and the coverage policy — what quantity per period is the plan approving, and on what basis? 2. Pull the FDA-approved prescribing label and identify the weight-based dosing formula for the prescribed agent. 3. Have the infusion center or specialty pharmacy document the patient's current weight and the exact quantity required per the label formula. 4. File an internal appeal with this calculation as the central exhibit. 5. If denied internally, escalate to external review immediately.

## Documentation to Gather

• Current weight documentation: Chart note or nursing weight measurement dated within the current prior-auth period, showing the patient's actual weight.
• Dosing calculation worksheet: A document (from the infusion center or prescriber's office) showing the label-based calculation that produces the prescribed quantity — without asserting specific numbers not in your own chart.
• FDA prescribing label: The relevant section describing the weight-based dosing framework for the approved indication.
• Prescriber letter: Statement that the prescribed quantity is the minimum necessary per the FDA label for the patient's current documented weight, and that a lower quantity would represent a sub-therapeutic dose inconsistent with the label.
• Prior infusion records: Documentation that the patient has been receiving this quantity without adverse events, supporting continuation.

## Criteria-Mapping Structure

Map the plan's quantity limit against the medical-necessity basis for the prescribed quantity:

| Plan Quantity Limit (per denial letter) | Prescribed Quantity Basis | |---|---| | Plan-authorized units per period | Label weight-based formula applied to current weight [date of weight measurement] | | Plan's stated rationale for limit | Prescriber rebuttal: label does not allow sub-therapeutic dosing; no clinical basis for reduction | | Prior authorization expiry / weight change | Updated weight on file; PA renewal request with current calculation attached |

Most quantity-limit appeals for weight-based rare-disease ERTs succeed when the weight documentation and dosing calculation are clear.